ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NSCI Netscientific Plc

63.00
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Netscientific Plc LSE:NSCI London Ordinary Share GB00BN4R5Q82 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 63.00 61.00 65.00 63.00 63.00 63.00 14,893 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1M -3.09M -0.1312 -4.80 14.85M
Netscientific Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NSCI. The last closing price for Netscientific was 63p. Over the last year, Netscientific shares have traded in a share price range of 49.00p to 80.50p.

Netscientific currently has 23,574,303 shares in issue. The market capitalisation of Netscientific is £14.85 million. Netscientific has a price to earnings ratio (PE ratio) of -4.80.

Netscientific Share Discussion Threads

Showing 276 to 296 of 5750 messages
Chat Pages: Latest  14  13  12  11  10  9  8  7  6  5  4  3  Older
DateSubjectAuthorDiscuss
06/6/2015
12:24
Thanks for your efforts protean and especially howdlep. I was planning to do the same thing.

I doubt that Woodford will extend his holding now, unless there is a dilution. When he was with Invesco, it was very common for him to hold just under the 30% limit in various 'story' shares.

Still great news though.

bamboo2
06/6/2015
11:55
Prior to yesterday's holding notifications, I have used Netscientific's AIM Rule 26 disclosure as of 3 March 2015 for the current positions.

Please note, I am aware that the link kindly provided by protean is more accurate to two decimal places, but the holding notifications from yesterday are based on the prior percentage positions, as per Netscientifics AIM Rule 26 disclosure.



OK prior to yesterday

Name Amount of shares %

Azima Family Trusts 17,152,020 47.8

(N.B The Azima Family Trusts combine Zahra Holding Ltd, White Mustard Investments Ltd and Cyrus Holdings)

(N.B, White Mustard Investments Ltd formerly known as Quantadyne Limited)

Zahra Holdings Ltd 11,795,000 32.9
Invesco Ltd 8,641,500 24.1
Woodford Investment Management 6,995,125 19.5
White Mustard Investments Ltd 3,430,000 9.6
Cyrus Holdings 1,927,020 5.4

Total 32,788,645 91.3

After yesterday's notifications

Zahra Holdings Ltd 11,795,000 18.2
Invesco Ltd 8,641,500 24.1
Woodford Investment Management 6,995,125 29.4
White Mustard Investments Ltd 3,430,000 8.8
Cyrus Holdings 1,927,020 3.4
J O Hambro 2,600,000 7.24

Total 32,788,645 91.14


So the amoumt of shares in the hands of 3%+ major shareholders is relatively unchanged (using 1 decimal place creates a slight variance).

HOWEVER

the key thing here is that shares have been transferred from The Azima Family Trusts to Woodford Investment Management and to a new player, J O Hambro.

Critically, Woodford Invstment Management are now just short of a MANDATORY TAKEOVER of NSCI. However, Invesco Ltd or J O Hambro could acquire a 30% holding first.

Who will make the next move to acquire control?

The winner will be NSCI shareholders....

howdlep
05/6/2015
23:49
Major Shareholders listed here but not yet updated to take into account today's RNSes:
protean
05/6/2015
19:23
Cyrus Holdings Limited sell 696,567 to hold 1,230,453 or 3.4%

White Mustard Investments Ltd sell 250,000 to hold 3,180,000 or 8.80%

Zahra Holdings Limited sell 5,253,433 to hold 6,541,567 or 18.2%


From the first holdings rns, "This form should be read together with the forms of White Mustard Investments Limited and Zahra Holdings Limited, also completed on this date, which together with Cyrus Holdings Limited in total held 17,152,020 shares representing 47.8 per cent of the Company's issued share capital prior to this notification and now hold 10,952,000 shares representing 30.5% of the Company's issued capital."

bamboo2
05/6/2015
18:49
Stock is tightening nicely so any hint of positive news should help to further the price

It's worth noting that I do not hold a position here but set up the thread as I was interested in the stock

mirabeau
05/6/2015
18:47
Apparently 91.59% of shares owned by institutions.
pyglet
05/6/2015
15:55
Also J O HAMBRO CAPITAL MANAGEMENT LIMITED make a maiden holding announcement [afaik] of 2,600,000 or 7.24%
bamboo2
05/6/2015
14:29
daily candles. fibs show target for pennant using Bulkowskis formula
bamboo2
05/6/2015
14:23
breakout of £2+ today. no doubt the weekend papers will report on Woodfords increase here
65jack
05/6/2015
14:17
Very nice. The PDS holding alone justifies this rise.
bamboo2
05/6/2015
14:13
It looks like he's still adding as well, as we speak!
mirabeau
05/6/2015
10:48
Time for a secondary move higher and yes, this will move very quickly given the tiny free float
howdlep
01/6/2015
12:28
This stock is unbelievably illiquid. The price moves on even the smallest of trades
mirabeau
31/5/2015
23:13
Been reading up, Merck seem to be one of the leading major pharmas in cancer immunotherapies.

PDS Current Partners

EMD-Millipore, Schaffhausen, Switzerland: A division of EMD-Millipore, Merck Cie, has developed a proprietary process to manufacture the patented structurally-specific lipid used in the Versamune® vector. Merck Cie has granted PDS Biotechnology an exclusive worldwide commercial license to utilize the chiral lipid in immunotherapies and based on the Versamune® vector technology. Merck Cie will provide the lipid manufactured under cGMP conditions for use in the clinical and commercial drug products developed with PDS Biotechnology’s Versamune® technology.

Merck KGaA, Darmstadt, Germany: In 2012 PDS granted Merck KGaA an exclusive worldwide license to utilize PDS Biotechnology’s novel Versamune® technology in selected next-generation cancer immunotherapies in preclinical development. One of these products is anticipated to enter phase 1 clinical trials in 2015.

Nanotechnology Characterization Lab (NCL)/ National Cancer Institute (NCI): PDS Biotechnology Corporation was been selected as an affiliate of the NCL. The NCL is a collaboration between the NCI, Food and Drug Administration (FDA) and the National Institute of Standards and Technologies (NIST). The NCL’s goal is to select the most promising cancer nanotechnologies and work with the companies to get their products rapidly through regulatory submissions with the FDA. PDS Biotechnology collaborated with the NCL to perform pre-clinical studies for PDS Biotechnology’s Versamune®–based HPV cancer immunotherapy

bamboo2
29/5/2015
15:07
Look at the sells, MMS taking a 5p discount for 2.5k sells.

Sub 160p is coming in the close, me thinkgs

the infidel
29/5/2015
14:10
AMC has breached 20p chaps.
bad robot
29/5/2015
13:58
Read my posts, I said buyers sucked in the intraday today and if you are talking about yesterday news, then it should be irrelevant to you. Doh

Anything else you want clarification?


BCKTTSIM 29 May'15 - 13:44 - 276 of 277 0 0

What makes you think I'm sucked in .

bad robot
29/5/2015
13:44
What makes you think I'm sucked in .Came out , made a bit on TRT which you have missed, came back in and since then it's gone up.I would concentrate on leading the lambs to slaughter if I were you.
bckttsim
29/5/2015
13:31
so another rns today at the same time?

Do you think I should play last week number for euromillions


BCKTTSIM 29 May'15 - 13:17 - 273 of 274 0 0

It took off after 2pm yesterday ......repeat today

bad robot
29/5/2015
13:17
The mugs got sucked in. IMHO
bad robot
29/5/2015
13:17
It took off after 2pm yesterday ......repeat today
bckttsim
Chat Pages: Latest  14  13  12  11  10  9  8  7  6  5  4  3  Older

Your Recent History

Delayed Upgrade Clock